Expanding roles in myeloma: Kraeber-Bodéré and colleagues review new developments in multiple myeloma treatment, including prognostic evaluation and response assessment, with an emphasis on nuclear medicine techniques. . . . . ***Page 1331***

Auger electron–emitting therapy potential: Bolcaen and colleagues summarize expert perspectives on the current status of Auger electron radiopharmaceutical therapy, identify hurdles to development, and make recommendations for future research. . . . . ***Page 1344***

Future of U.S. nuclear medicine: Graham offers perspective on the implications of nuclear medicine workforce shortages and outlines recommendations for meeting the challenges of training physicians in this rapidly evolving discipline. . . . . ***Page 1352***

ABNM looks at nuclear medicine future: Segall and colleagues provide data from the American Board of Nuclear Medicine on declining numbers of nuclear medicine residents in training and the effects of new pathways to certification, including dual training programs. . . . . ***Page 1354***

Stronger together: Grady and colleagues look at the multidisciplinary history of radiopharmaceutical imaging and therapy and emphasize the importance of inclusivity in nuclear medicine training to encompass collaboration and cooperation across existing boundaries. . . . . ***Page 1356***

Redefining nuclear medicine for the future: Czernin and Calais call for new standards with integrated programmatic and financial independence to strengthen future nuclear medicine training with breakthrough technologies that attract young talent. . . . . ***Page 1359***

Toward integrated independence: Johannes Czernin discusses the future of radiolabeled theranostics and associated training and practice with subject-matter leaders Ebrahim Delpassand, Eric Rohren, and Wolfgang Weber. . . . . ***Page 1361***

ABY-025 PET in HER2 breast cancer: Alhuseinalkhudhur and colleagues investigate uptake of this ^{68}Ga-labeled human epidermal growth factor receptor 2–binding PET tracer in biopsy results and early treatment response in primary and metastatic breast cancer. . . . . ***Page 1364***

[^{18}F]FDG PET/CT in sarcoma: Metser and colleagues determine the impact of [^{18}F]FDG PET/CT on initial staging, restaging, clinical management, and outcomes of patients with soft-tissue and bone sarcomas and negative/equivocal findings for metastases or limited recurrence on conventional work-up. . . . . ***Page 1371***

Targeting CD206 in humans: Gondry and colleagues evaluate the safety, biodistribution, dosimetry, and tumor uptake of a [^{68}Ga]Ga-NOTA-anti-CD206 single-domain antibody tracer targeting antiinflammatory macrophages in patients with solid tumors. . . . . ***Page 1378***

^{68}Ga-FAPI PET/CT and ECD: Ma and colleagues explore the ability of ^{68}Ga–fibroblast activation protein inhibitor PET/CT to detect and differentiate lesions in patients with Erdheim–Chester disease. . . . . ***Page 1385***

Pain outcomes and ^{223}Ra therapy: Palmedo and colleagues detail the results of a study of pain- and bone pain–related quality of life in patients with metastatic castration-resistant prostate cancer and symptomatic bone metastases receiving ^{223}Ra. . . . . ***Page 1392***

^{68}Ga-FAPI and ^{18}F-FDG PET/CT in lymphoma: Chen and colleagues compare the diagnostic performance of ^{68}Ga-labeled fibroblast activation protein inhibitor and ^{18}F-FDG PET/CT in diagnosing lymphomas and characterize the influence of associated markers on tracer uptake by involved lesions. . . . . ***Page 1399***

SSTR antagonist PET/CT in NETs: Lin and colleagues contrast the performances of ^{68}Ga-DOTATATE and ^{68}Ga-NODAGA-JR11, a novel somatostatin receptor antagonist, in whole-body PET imaging of patients with metastatic, well-differentiated neuroendocrine tumors. . . . . ***Page 1406***

Hypocalcemia in ^{177}Lu-PSMA responders: Kumar and colleagues present case reviews of 2 men with marked hypocalcemic osteosclerotic responses to ^{177}Lu-PSMA-I&T therapy, with additional data estimating the general clinical incidence of such responses. . . . . ***Page 1412***

Appropriate use of ^{177}Lu-PSMA-617 RLT: Hope and colleagues provide an SNMMI expert consensus document with standardized guidance for selection and management of patients for ^{177}Lu-PSMA radioligand therapy. . . . ***Page 1417***

CXCR4-directed endoradiotherapy of DSRCT: Hartlapp and colleagues report on experience with the clinical potential of C-X-C motif chemokine receptor 4–directed imaging and endoradiotherapy in desmoplastic small round cell tumors, a rare sarcoma subtype. . . . . ***Page 1424***

^{177}Lu-PSMA kinetic assessment: Straub and colleagues use posttherapy SPECT/CT to test the hypothesis that ^{177}Lu-PSMA-617 tracer kinetics within tumors may influence treatment effectiveness in metastasized castration-resistant prostate cancer. . . . . ***Page 1431***

^{225}Ac-PRIT for peritoneal carcinomatosis: Chung and colleagues investigate the use of human epidermal growth factor receptor 2 ^{225}Ac-pretargeted radioimmunotherapy to treat a mouse model of human epithelial ovarian carcinoma SKOV3 xenografts growing as peritoneal carcinomatosis. . . . . ***Page 1439***

^{225}Ac PRIT in ovarian cancer: Li and colleagues provide context and commentary on preclinical research published in this issue of *JNM* on a promising pretargeted radioimmunotherapeutic approach for treating HER2-expressing ovarian peritoneal carcinomatosis. . . . . ***Page 1446***

FAPI tetramers in cancer theranostics: Pang and colleagues evaluate the tumor-targeting characteristics of radiolabeled fibroblast activation protein inhibitor multimers in vitro and in vivo, with implications for design of new FAP-targeted agents based on the polyvalency principle. . . . . ***Page 1449***

Red marrow uptake of [^{177}Lu]Lu-DOTATATE: Hemmingsson and colleagues use SPECT/CT after the first [^{177}Lu]Lu-DOTATATE treatment cycle in neuroendocrine neoplasms to identify and quantify specific red marrow uptake. . . . . ***Page 1456***

Data-driven STP dosimetry: Wang and colleagues detail patient data–driven regression models to reduce sensitivity to time-point selection in dosimetry-guided radiopharmaceutical therapy and compare these new models with commonly used single-time-point methods. . . . . ***Page 1463***

MC ^{90}Y vial activity assessments: Auditore and colleagues use Monte Carlo simulations to investigate the causes of observed discrepancies between PET/CT-measured and vendor-calibrated activities for ^{90}Y glass and resin microspheres. . . . . ***Page 1471***

Coronary ^{18}F-fluoride uptake: Daghem and colleagues characterize the natural history of coronary ^{18}F-fluoride uptake over 12 mo in patients with advanced chronic coronary artery disease or recent myocardial infarction. . . . . ***Page 1478***

^{18}F-NaF PET in murine CAVD: Ahmad and colleagues explore the utility of ^{18}F-NaF PET/CT for tracking murine aortic valve calcification and examine development of calcification with aging and its interdependence with bicuspid aortic valve and aortic stenosis. . . . . ***Page 1487***

[^{18}F]SNFT-1 for tau PET imaging: Harada and colleagues elucidate the binding properties of this novel tracer with high sensitivity and specificity to tau pathology in Alzheimer disease and compare it with other reported ^{18}F-labeled tau tracers. . . . . ***Page 1495***

PSMA-negative lesion progression: Murthy and colleagues present a case study of a patient with metastatic castration-resistant prostate cancer treated with 5 cycles of ^{177}Lu-PSMA radioligand therapy. . . . . ***Page 1502***